{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:35:48Z","timestamp":1773221748498,"version":"3.50.1"},"reference-count":63,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Discovery"],"published-print":{"date-parts":[[2023,3,4]]},"DOI":"10.1080\/17460441.2023.2170348","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T22:07:49Z","timestamp":1673993269000},"page":"231-245","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-3657","authenticated-orcid":false,"given":"Irma","family":"Convertino","sequence":"first","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7549-1807","authenticated-orcid":false,"given":"Sara","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0386-3816","authenticated-orcid":false,"given":"Emiliano","family":"Cappello","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1616-8644","authenticated-orcid":false,"given":"Giulia","family":"Valdiserra","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8813-2902","authenticated-orcid":false,"given":"Marco","family":"Bonaso","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-8486","authenticated-orcid":false,"given":"Marco","family":"Tuccori","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"},{"name":"Unit of Adverse Drug Reactions Monitoring, Pisa University Hospital, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"cit0001","unstructured":"Cromer Berman S Emergency Use Authorization (EUA) for EVUSHELD (Tixagevimab 150 mg and Ci lgavimab 150 mg injection co-packaged for intramuscular use) center for drug evaluation and research (CDER) review identifying information application type (EUA or Pre-EUA) EUA If E. FDA website. https:\/\/www.fda.gov\/media\/155107\/download. Published 2021. Accessed 2021. Accessed Jun 27, 2022 Jun 27."},{"key":"cit0002","unstructured":"Evusheld | European medicines agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evusheld. Published 2022. Accessed 2022. Accessed Oct 10, 2022 Oct 10."},{"key":"cit0003","unstructured":"Agenzia Italiana del Farmaco (AIFA). AIFA autorizza l\u2019utilizzo terapeutico del monoclonale Evusheld per il trattamento precoce del COVID-19 in soggetti a rischio di progressione. AIFA official website. https:\/\/www.aifa.gov.it\/-\/aifa-autorizza-l-utilizzo-terapeutico-del-monoclonale-evusheld-per-il-trattamento-precoce-del-covid-19-in-soggetti-a-rischio-di-progressione. Accessed 2022 Oct 10."},{"key":"cit0004","unstructured":"EMA Committee for Medicinal Products for Human Use (CHMP). Committee for medicinal products for human use (CHMP) assessment report. EMA website. www.ema.europa.eu\/contact. Published 2021. Accessed June 27, 2022."},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.3390\/v14091999"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001916"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01285-13"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1601"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1084\/JEM.20201993"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.2014296"},{"key":"cit0011","unstructured":"Randomized A, Open-label, Dose-ranging Study in Adults and Pediatric Individuals \u2265 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 - Full Text View - ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05375760?term=cilgavimab&draw=2&rank=2. Accessed 2022 Jun 10."},{"key":"cit0012","unstructured":"Non-inferiority Trial on Treatments in Early COVID-19 - Full Text View - ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05321394?term=cilgavimab&draw=2&rank=3. Accessed 2022 Jun 10."},{"key":"cit0013","unstructured":"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT) - Full Text View - ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04625725?term=AZD7442&draw=2&rank=6. Accessed 2022 Jun 10."},{"key":"cit0014","unstructured":"Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults - Full Text View - ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04723394?term=AZD7442&draw=2&rank=4. Accessed 2022 Jun 10."},{"key":"cit0015","unstructured":"A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05184062?term=NCT05184062&draw=2&rank=1. Accessed 2022 Aug 10."},{"key":"cit0016","unstructured":"A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05437289?term=NCT05437289&draw=2&rank=1. Accessed 2022 Oct 3."},{"key":"cit0017","unstructured":"Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05438498?term=NCT05438498&draw=2&rank=1. Accessed 2022 Oct 3."},{"key":"cit0018","unstructured":"ACTIV-3: therapeutics for Inpatients With COVID-19 - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04501978?term=NCT04501978&draw=2&rank=1. Accessed 2022 Oct 4."},{"key":"cit0019","unstructured":"Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19 - Full Text View - ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05271929?term=cilgavimab&draw=2&rank=5. Accessed 2022 Jun 10."},{"key":"cit0020","unstructured":"AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics - Full Text View - ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05281601?term=AZD7442&draw=2&rank=1. Accessed 2022 Jun 10."},{"key":"cit0021","unstructured":"Double-blind PI, Placebo-controlled Study of AZD7442 - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04896541?term=NCT04896541&draw=2&rank=1. Accessed 2022 Oct 4."},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.ABL8124"},{"key":"cit0023","unstructured":"Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05166421?term=NCT05166421&draw=2&rank=1. Accessed 2022 Aug 10."},{"key":"cit0024","unstructured":"Trial of Treatments for COVID-19 in Hospitalized Adults - Full Text View - ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04315948?term=AZD7442&draw=3&rank=12. Accessed 2022 Jun 14."},{"key":"cit0025","unstructured":"ACTIV-2: a Study for Outpatients With COVID-19 - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04518410. Accessed 2022 Aug 10."},{"key":"cit0026","unstructured":"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults - Full Text View - ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04625972?term=AZD7442&draw=2&rank=5. Accessed 2022 Jun 10."},{"key":"cit0027","unstructured":"Double-blind PI, Placebo-controlled Study of AZD7442 - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05406375?term=NCT05406375&draw=2&rank=1. Accessed 2022 Aug 10."},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116620"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00180-1"},{"key":"cit0030","unstructured":"AstraZeneca. Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19. AstraZeneca web. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2021\/update-on-azd7442-storm-chaser-trial.html. Published 2021. Accessed 2021. Accessed Jun 27, 2022 Jun 27."},{"key":"cit0031","unstructured":"Tracking SARS-CoV-2 variants. who.int website. Accessed 2022 Dec 4. https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2022.04.006"},{"key":"cit0033","unstructured":"Danner C. What We Know: new COVID Variants BQ.1, BQ.1.1, XBB, BF.7. Intelligencer vox media. https:\/\/web.archive.org\/web\/20221101115417\/https:\/\/nymag.com\/intelligencer\/article\/what-to-know-new-covid-variants-bq-1-bq-1-1-xbb-bf-7.html. Published 2022. Accessed 2022. Accessed Dec 13, 2022 Dec 13."},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1101\/2022.12.06.22283000"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1101\/2022.09.16.22280034"},{"key":"cit0036","unstructured":"Evusheld | European Medicines Agency. EMA website. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evusheld. Published 2022. Accessed 2022. Accessed Jul 4, 2022 Jul 4."},{"key":"cit0037","unstructured":"AIFA authorises the therapeutic use of the monoclonal Evusheld for the early treatment of COVID-19. https:\/\/www.aifa.gov.it\/en\/-\/aifa-autorizza-l-utilizzo-terapeutico-del-monoclonale-evusheld-per-il-trattamento-precoce-del-covid-19-in-soggetti-a-rischio-di-progressione. Published 2022. Accessed 2022. Accessed Oct 10, 2022 Oct 10."},{"key":"cit0038","unstructured":"Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries (EVOLVE) - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05315323. Accessed 2022 Jul 4."},{"key":"cit0039","unstructured":"Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort. (PRECOVIM) - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05216588. Accessed 2022 Jul 4."},{"key":"cit0040","unstructured":"Tixagevimab\/cilgavimab - Protection of Covid-19 in Transplanted Patients (TIXCI-TRANS) - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05234398. Accessed 2022 Jul 4."},{"key":"cit0041","unstructured":"A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies (COVIMAB) - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05439044. Accessed 2022 Jul 4."},{"key":"cit0042","unstructured":"PREP (Pre-Exposure Prophylaxis) of COVID-19 - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT05461378?term=NCT05461378&draw=2&rank=1. Accessed 2022 Oct 4."},{"key":"cit0043","unstructured":"eVusheld Assessment reaL wORld Effectiveness in DoD Health System - Full Text View - ClinicalTrials.gov. ClinicalTrial.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05569408. Accessed 2022 Dec 20."},{"key":"cit0044","unstructured":"EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS - Full Text View - ClinicalTrials.gov. ClinicalTrial.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05629923?term=NCT05629923&draw=2&rank=1. Accessed 2022 Dec 20."},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.17128"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.05.008"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.17121"},{"key":"cit0048","unstructured":"FDA releases important information about risk of COVID-19 due to certain variants not neutralized by Evusheld | FDA. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-releases-important-information-about-risk-covid-19-due-certain-variants-not-neutralized-evusheld. Accessed 2022 Oct 4."},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1101\/2022.05.24.22275467"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1101\/2022.05.28.22275716"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.07.015"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2022.08.019"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1093\/CID\/CIAC625"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.07.014"},{"issue":"6","key":"cit0055","volume":"28","author":"Kimura I","year":"2022","journal-title":"bioRxiv"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1101\/2022.09.30.22280568"},{"key":"cit0057","unstructured":"European Centre for Disease Prevention and Control. Antiviral resistance monitoring capability and capacity for SARS-CoV-2 and influenza within the EU\/EEA. ECDC website. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/sars-cov-2-and-influenza-antiviral-resistance-monitoring-capability. Published 2022. Accessed 2022. Accessed Dec 19, 2022 Dec 19."},{"key":"cit0058","unstructured":"FDA Adverse Events Reporting System (FAERS) Public Dashboard last access 2022 Oct 4. https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/45beeb74-30ab-46be-8267-5756582633b4\/state\/analysis. Published 2022. Accessed 2022. Accessed Oct 4, 2022 Oct 4."},{"key":"cit0059","unstructured":"Cromer Berman S Emergency Use Authorization (EUA) for Sotrovimab 500 mg Center for Drug Evaluation and Research (CDER) - Memorandum May 2022. FDA website. https:\/\/www.fda.gov\/drugs\/coronavirus-covid-19-drugs\/cder-scientific-review-documents-supporting-emergency-use-authorizations-drug-and-biological. Published 2022."},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00311-5"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2021.1960819"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2022.2058486"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11080823"}],"container-title":["Expert Opinion on Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17460441.2023.2170348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T10:51:11Z","timestamp":1677667871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17460441.2023.2170348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,4]]}},"alternative-id":["10.1080\/17460441.2023.2170348"],"URL":"https:\/\/doi.org\/10.1080\/17460441.2023.2170348","relation":{},"ISSN":["1746-0441","1746-045X"],"issn-type":[{"value":"1746-0441","type":"print"},{"value":"1746-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}